<?xml version="1.0" encoding="UTF-8"?>
<p class="p">Nobili and colleagues evaluated the impact of DHA supplementation at low or high doses (250â€“500 mg/die) for six months vs. placebo on hepatic steatosis detected by ultrasonography, in a cohort of 60 children with NAFLD. DHA supplementation, in a non-dependent dose manner, resulted in less severe hepatic disease, reduction of triglycerides, and an increase in insulin sensitivity, but had no effect, neither on alanine transaminase levels nor body mass index [
 <xref rid="B47-ijms-20-02118" ref-type="bibr" class="xref">47</xref>]. In contrast with this finding, another study reported that in 201 obese and insulin-resistant children and adolescents who were randomized to receive 500 mg of metformin or 1.8 g of n-3 PUFAs for 12 weeks, n-3 FAs decreased glucose and insulin levels (reducing HOMA-IR values and also having a meaningful impact on BMI [
 <xref rid="B48-ijms-20-02118" ref-type="bibr" class="xref">48</xref>]. 
</p>
